IDH1 and acute myeloid leukemia: The standard therapeutic approach is a combined cytarabine and anthracycline-based regimen followed by consolidation with allogeneic stem cell transplantation (allo-SCT) for high-risk AML and allo-SCT for non-high-risk patients only in second CR after relapse [32,33].In the last decade, several drugs such as epigenetic treatments, i.e., hypomethylating agents or histone-deacetylaseinhibitors, anti-CD33–ozogamicin conjugated monoclonal antibodies, and FLT3 and isocitrate dehydrogenase (IDH) inhibitors were used to treat pediatric and adult AML (Table 2).